5Y6 Stock Chart & Stats
€9.45
€0.15(1.61%)
At close: 4:00 PM EDT
€9.45
€0.15(1.61%)
Day’s Range― - ―
52-Week Range€3.38 - €13.30
Previous CloseN/A
Volume350.00
Average Volume (3M)361.00
Market Cap
€1.67B
Enterprise Value€1.53K
Total Cash (Recent Filing)€433.30M
Total Debt (Recent Filing)€54.63M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Oct 29, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.62
Shares Outstanding138,476,820
10 Day Avg. Volume103
30 Day Avg. Volume361
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.89Price Target Upside121.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-1.96
Revenue Forecast (FY)€1.74M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy (Phase III)Two independent Phase III readouts showing statistically significant primary endpoint results, rapid onset (as early as Day 1) and maintained benefit through six months materially reduce clinical risk. Durable efficacy strengthens the regulatory case, supports prescriber confidence and underpins longer-term commercial potential.
Prescriber Willingness & TrainingExtremely high prescriber intent (~90%) and early training activity (>1,000 people trained on the psychedelic portion) create a favorable uptake foundation. Strong clinician willingness plus scalable training reduces early adoption friction and supports a faster commercial ramp if regulatory and access hurdles are cleared.
Cash Runway And Low LeverageA $433M cash balance and management's runway guidance into 2028 provide a meaningful near-term funding cushion to complete the rolling NDA, finalize REMS planning, recruit a commercial team, and support early launch activities without immediate dilutive financing, aided by very low reported debt levels.
Bears Say
Pre-revenue With Growing LossesThe company remains pre-revenue while R&D and operating spend have accelerated, producing very large trailing losses and persistent negative operating cash flow. This structural cash burn means long-term viability depends on successful approval and commercialization, leaving funding and execution risk until revenues materialize.
Equity Volatility / Negative EquityReported negative equity in 2025 signals a thin shareholder cushion and volatile balance sheet. Even with low debt, negative equity increases the likelihood of future equity financing or dilution if commercialization timing slips, weakening long-term financial flexibility and investor protection.
Regulatory & Access Timing RisksCritical external dependencies—federal DEA rescheduling, REMS finalization post-approval, and incomplete payer reimbursement strategies—create structural timing and access risk. Even with approval, delays or restrictive REMS/payer decisions could materially slow patient access and revenue realization over the medium term.
COMPASS Pathways News
5Y6 FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was €3.38 and its highest was €13.30 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is €1.67B.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is Oct 29, 2026 which is in 75 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Aug 05, 2026. The company reported -€1.627 earnings per share for the quarter, missing the consensus estimate of -€0.336 by -€1.291.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -0.31.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 138,476,820 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -€1.627 in its last earnings report, missing expectations of -€0.336. Following the earnings report the stock price went up 0.521%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Currently, no hedge funds are holding shares in DE:5Y6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€20.89 (121.02% Upside)
€20.89 (121.02% Upside)
Blogger Sentiment
Bullish
DE:5Y6 Sentiment 96%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
160.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
71.89%
Trailing 12-Months
Company Description
COMPASS Pathways
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
5Y6 Company Deck
5Y6 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and commercial momentum: highly statistically significant Phase III efficacy, demonstrated 6-month durability, a generally favorable safety profile, an active rolling NDA with modules under review, a healthy cash position ($433M) through 2028, extensive commercial hiring, strong prescriber interest (~90% willing to prescribe), and substantial launch planning (training, payer engagement, partnerships). Key risks highlighted are timing and sequencing uncertainties around DEA rescheduling and REMS finalization, ongoing payer negotiations, remaining 52-week safety data submission, and potential competitive entrants. On balance, the positive clinical results and robust launch preparedness materially outweigh the timing and regulatory uncertainties.View all DE:5Y6 earnings summaries5Y6 Stock 12 Month Forecast
Average Price Target
€20.89
▲(121.02% Upside)